References
- Moss P., Gillespie G., Frodsheim P., Bell J., Reybum H. Clonal populations of CD4+ and CD8+ T cells in patients with multiple myeloma and paraproteinemia. Blood 1996; 87: 3297–3306
- Kay N. E., Oken M. M., Kyle R., Van Ness B., Kalish L., Leong T., Griepp P. Sequential phenotyping of myeloma patients on chemotherapy: persistence of activated T cells and natural killer cells. Leuk Lymphoma 1995; 16: 351–354
- Massai M., Bianchi A., Attsiano C., Peola S., Redoglia V., Diazani U., Pileri A. Rapid generation of anti-plasma cell activity in the bone marrow of patients with CD3-activated T cells. Blood 1992; 82: 1787–1797
- Mills K. H., Cawley J. C. Abnormal monoclonal antibody-defined helper/suppressor T-cell subpopulations in multiple myeloma: relationship to treatment and clinical stage. Br J Haematol 1983; 53: 271–275
- Serra H. M., Mant M. J., Ruether B. A., Ledbetter J. A., Pilarski L. M. Selective loss of CD4+ CD45R T cells in peripheral blood of multiple myeloma patients. J Clin Immunol 1988; 259–265
- San Miguel J. F., Gonzalez M., Gascon A., Moro M. J., Hernandez J. M., Ortega F., Jimenez R., Guerras L., Romero M., Cassanova F. Lymphoid subsets and prognostic factors in multiple myeloma. Br J Haematol 1992; 80: 305–309
- Brown R. D., Yuen E., Nelson M., Gibson J., Joshua D. E. The prognostic significance of T cell receptor P gene rearrangements and idiotype-reactive T cells in multiple myeloma. Leukemia 1996; 11: 1312–1317
- Schultze J., Nadler L. M., Gribben J. G. B7-mediated costimulation and the immune response. Blood Rev 1996; 10: 111–127
- Hellstrom K. E., Hellstrom I., Chen L. Can costimulated tumor immunity be therapeutically efficacious?. Immunol Rev 1995; 145: 123–145
- Allison J. P., Hurwitz A. A., Leach D. R. Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr Opinion Immunol 1995; 7: 682–686
- Freedman G. J., Freedman A. S., Horowitz J. C., Daley J., Nadler L. M. B7, a B-cell restricted antigen that identifies preactivated B cells. J Immunol 1987; 139: 3260–3267
- Kornbluth J. Potential role of CD28-B7 interactions in the growth of of myeloma plasma cells. Curr Topics Microbiol Immunol 1995; 194: 43–49
- Joshua D. E., Penny R., Mathews J. P., Laidlaw C. R., Gibson J., Bradstock K., Wolf M., Goldstein D. Australian Leukaemia Study Group Myeloma II: a randomized trial of intensive combination chemotherapy with or without interferon in patients with myeloma. Br J Haematol 1997; 97: 38–45
- Hata H., Xiao H., Petrucci M. T., Woodliff J., Chang R., Epstein J. Interleukin-6 gene expression in multiple myeloma: a characteristic of immature tumor cells. Blood 1993; 81: 3357–3364
- Joshua D. E., Petersen A., Brown R., Pope B., Snowdon L., Gibson J. The labelling index of primitive plasma cells determines the clinical behaviour of patients with myelomatosis. Br J Haematol 1996; 94: 76–81
- Linsley P. S., Bradshaw J., Urnes M., Grosmaire L., Ledbetter J. A. CD28 engagement by B7/BB-1 induces transient down-regulation of CD28 synthesis and prolonged unresponsiveness to CD28 signaling. J Immunol 1993; 150: 3161–3169
- Dunussi-Joannopolous K., Weinstein H. J., Nickerson P. W., Strom T. B., Burakoff S. J., Croop J. M., Arceci R. J. Irradiated B7–1 transduced promary acute myelogenous leukaemia (AML) cells can be used as therapeutic vaccined in murine AML. Blood 1996; 87: 2938–2946
- Matulonis U., Dosiou C., Freeman G., Lamont C., Mauch P., Nadler L. M., Griffin J. D. B7–1 is superior to B7–2 costimulation in the induction and maintenance of T cell mediated antileukaemia immunity. J Immunol 1996; 156: 1126–1131